Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD
| Status: | Recruiting |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 20 - 85 |
| Updated: | 1/27/2019 |
| Start Date: | December 18, 2018 |
| End Date: | February 2021 |
| Contact: | Fatemeh Adlparvar |
| Email: | Fatemeh.Adlparvar@nyumc.org |
| Phone: | 212 263 0380 |
Developing Advanced Blood-Brain Barrier Permeability Imaging for Early Alzheimer's Disease
Aging is the primary risk factor in aging-related dementia. An important initiating factor
for the development and progression of cognitive impairment is disruption of the blood-brain
barrier (BBB). BBB plays an important role in maintaining normal brain homeostasis and
protecting neural tissues from toxins. It is hypothesized that such changes known to be
common in aging and can be an early process that precedes Alzheimer's Disease (AD). The
microvascular changes related to subtle BBB disruption can be measured with
permeability-surface area (PS) derived from GRASP DCE-MRI acquired less than 10 minutes, and
the patterns of increased PS in normal and abnormal aging are different.
for the development and progression of cognitive impairment is disruption of the blood-brain
barrier (BBB). BBB plays an important role in maintaining normal brain homeostasis and
protecting neural tissues from toxins. It is hypothesized that such changes known to be
common in aging and can be an early process that precedes Alzheimer's Disease (AD). The
microvascular changes related to subtle BBB disruption can be measured with
permeability-surface area (PS) derived from GRASP DCE-MRI acquired less than 10 minutes, and
the patterns of increased PS in normal and abnormal aging are different.
Inclusion Criteria:
- Subjects that have been diagnosed with aMCI ages 65-85
Exclusion Criteria:
- Pregnant, planning to get pregnant, or nursing.
- Claustrophobia
- Cardiac pacemaker
- Intracranial clips, metal implants, unremovable jewelries, metal in eyes.
- History or presence of any other major medical, neurologic or psychiatric conditions,
such as Alzheimer's diseases, Parkinson's diseases, and stroke.
- Renal or liver disease as this may cause concerns related to Gad-based contrast agent
- Allergy to the contrast agent Gadolinium
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Yulin Ge, MD
Phone: 212-263-7744
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
